Publications by authors named "Kalluru Hindu"
Background: Vupanorsen is a GalNAc-conjugated antisense oligonucleotide targeting angiopoietin-like 3 (ANGPTL3) mRNA shown to reduce atherogenic lipoproteins in individuals with dyslipidemia.
Objectives: The aim of this study was to satisfy Chinese regulatory requirements and support ethnic sensitivity assessment by evaluating pharmacokinetics (PK), pharmacodynamics (PD), and safety of vupanorsen in healthy Chinese adults with elevated triglycerides (TG).
Methods: In this phase I, parallel-cohort, open-label study, 18 Chinese adults with elevated fasting TG (≥ 90 mg/dL) were randomized 1:1 to receive a single subcutaneous dose of vupanorsen 80 mg or 160 mg.
Vupanorsen (PF-07285557) is a second-generation tri-N-acetyl galactosamine (GalNAc )-antisense oligonucleotide targeted to angiopoietin-like 3 (ANGPTL3) mRNA, shown to reduce lipids and apolipoproteins in subjects with dyslipidemia. To aid bringing innovative drugs to global patients efficiently, a multi-purpose Japanese phase I study was conducted, with integrated development approaches agreed by the Pharmaceuticals and Medical Devices Agency (PMDA). This randomized, double-blind, placebo-controlled, single-ascending dose (SAD) study investigated the safety, tolerability, pharmacokinetics, and pharmacodynamics of vupanorsen administered subcutaneously to Japanese adults (20-65 years) with elevated triglycerides (TG).
View Article and Find Full Text PDFArticle Synopsis
- Ritlecitinib is being developed as a treatment for inflammatory diseases and inhibits certain transport proteins such as OCT1.
- A clinical study showed that when ritlecitinib is taken with sumatriptan (a drug that relies on OCT1), its concentration in the bloodstream increased significantly, indicating that ritlecitinib affects OCT1’s function.
- The study confirmed that while ritlecitinib and its metabolite M2 inhibit OCT1, they do not have a meaningful impact on other transporters like OCT2 or MATE1/2K.
Turmeric is one of the most used herbal supplements among cancer patients. It reportedly modulates the function of CYP450 enzymes and drug transporters. This study investigates the effect of turmeric on the pharmacokinetics of paclitaxel in breast cancer patients.
View Article and Find Full Text PDFArticle Synopsis
- Herbal supplements (HS) are frequently used by cancer patients, with a notable 26% of participants in a study reported as users, mainly for symptom relief and influenced by friends and family.
- The study analyzed the prevalence of HS usage among 220 cancer patients at a medical center in India, highlighting significant predictors such as chemotherapy and unemployment.
- There is a concerning trend of non-disclosure of HS use to healthcare providers, driven primarily by fear of disapproval, stressing the need for further research on the impacts of herb-drug interactions in cancer treatment.
Background: and purpose: Phytochemicals are proven to be effective in targeting numerous signaling pathways in cancer. Utilizing plant-based support in combination with currently approved chemotherapeutic strategies might prove a feasible method to improve therapeutic outcomes in cancer patients. The present study aimed to estimate the effect of turmeric supplementation on quality of life (QoL) and hematological parameters in breast cancer patients on Paclitaxel chemotherapy.
View Article and Find Full Text PDF